Low-Dose Paclitaxel-Coated Balloon Angioplasty versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: 6-Month Results in a Tertiary Care Hospital of Central India

Abstract

Introduction Superficial femoral and popliteal arteries are the most common locations of peripheral vascular disease (PVD). Endovascular interventional therapy including drug-coated balloon (DEB) angioplasty or percutaneous transluminal angioplasty (PTA) and stenting are important options for treatment of PVD.

Aims and Objectives The main objective is to compare the efficacy of DEB over PTA with optional stenting in management of obstructive femoropopliteal lesions in terms of 6-month patency rate.

Materials and Methods The clinical experimental study was carried out in a tertiary care center over duration of 2 years. All symptomatic patients having lower limb PVD in femoropopliteal segment were included. Total 37 patients were included in this study in which 16 underwent plain balloon angioplasty (with 3 patients undergoing bare metal stenting [BMS]) and 21 additional underwent DEB angioplasty. Patients with previously intervened lesions, primary lesion failure, major ischemic tissue loss, poor aortoiliac or common femoral inflow, or end-stage kidney disorders were excluded.

Result At 1-month follow-up, patency rates in DEB and conventional PTA ± BMS were 85.71% and 87.5%, respectively. On 6-month follow-up, patency rates were found to be 71.4% versus 37.5%, respectively (p = 0.039; significant). In case of occluded lesions, on 6-month follow-up, patency rate in DEB group was higher than that in plain balloon group (66.7% vs. 25%). In both the cohorts, success rate, i.e., patency rates were more in short and intermediate length lesions than long segment lesions. DEB was found to be superior to plain angioplasty with optional stenting in terms of 6-month patency rate.

Keywords

peripheral vascular disease - femoropopliteal - drug-eluting balloon angioplasty

• References

• 1 Khanna NN. Overview of peripheral vascular disease. Med Update 2005: 89-99
• 2 Mohan V, Premalatha G, Sastry NG. Peripheral vascular disease in non-insulin-dependent diabetes mellitus in south India. Diabetes Res Clin Pract 1995; 27 (03) 235-240
• 3 Pendsey SH. peripheral vascular disease: an Indian scenario. Diabetologia Croatica. 1998: 27-4 http://www.idb.hr/diabetologia/98no4-4.htmlProfessional
• 4 Newman AB. Peripheral arterial disease: insights from population studies of older adults. J Am Geriatr Soc 2000; 48 (09) 1157-1162
• 5 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Intersociety consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (01) Suppl S S5-S67
• 6 Kasapis C, Gurm HS. Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. Curr Cardiol Rev 2009; 5 (04) 296-311
• 7 Geronemus AR, Peña CS. Endovascular treatment of femoral-popliteal disease. Semin Intervent Radiol 2009; 26 (04) 303-314
• 8 Lin PH, Weakley SM, Kougias P. How to interpret data from the superficial femoral artery stenting trials and registries. Semin Vasc Surg 2010; 23 (03) 138-147
• 9 Schroeder H, Werner M, Meyer DR. et al; ILLUMENATE EU RCT Investigators. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation 2017; 135 (23) 2227-2236
• 10 Ott I, Cassese S, Groha P. et al. Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH). Circulation 2017; 135 (23) 2218-2226
• 11 Giacoppo D, Cassese S, Harada Y. et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv 2016; 9 (16) 1731-1742
• 12 Bausback Y, Willfort-Ehringer A, Sievert H. et al; RANGER SFA Investigators. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther 2017; 24 (04) 459-467
• 13 Tepe G, Laird J, Schneider P. et al; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015; 131 (05) 495-502
• 14 Iida O, Soga Y, Urasawa K. et al; MDT-2113 SFA Japan Investigators. Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther 2018; 25 (01) 109-117
• 15 Baril DT, Marone LK, Kim J, Go MR, Chaer RA, Rhee RY. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. J Vasc Surg 2008; 48 (03) 627-633
• 16 Micari A, Brodmann M, Keirse K. et al; IN.PACT Global Study Investigators. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT Global Study. JACC Cardiovasc Interv 2018; 11 (10) 945-953
• 17 Tepe G, Beschorner U, Ruether C. et al. Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther 2015; 22 (05) 727-733
• 18 Park UJ, Kim HT, Roh YN. Impact of tibial runoff on outcomes of endovascular treatment for femoropopliteal atherosclerotic lesions. Vasc Endovascular Surg 2018; 52 (07) 498-504
• 19 Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss. J Vasc Surg 2008; 48 (03) 619-625 discussion 625-626
• 20 Johnston KW, Rae M, Hogg-Johnston SA. et al. 5-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 1987; 206 (04) 403-413
• 21 Liistro F, Grotti S, Porto I. et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 2013; 6 (12) 1295-1302